Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Philip W. Kantoff(Convergent Science (United States)), Wayne R. Godfrey(Dana-Farber Cancer Institute), Thomas Schuetz(Dana-Farber Cancer Institute), L. Michael Glodé(Dana-Farber Cancer Institute), David L. Bilhartz(Dana-Farber Cancer Institute), Jeffrey Schlom(National Cancer Institute), Dennis Panicali(Dana-Farber Cancer Institute), James L. Gulley(National Cancer Institute), Brent A. Blumenstein(Dana-Farber Cancer Institute), Philip M. Arlen(Dana-Farber Cancer Institute), Reiner Laus(Dana-Farber Cancer Institute), Michael S. Wyand(Dana-Farber Cancer Institute), Kelledy Manson(Dana-Farber Cancer Institute), William L. Dahut(National Cancer Institute)
Cited by 973
Related Papers
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2010|5.5k
Gene expression correlates of clinical prostate cancer behavior
|Cancer Cell|2002|2.5k
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
|The Journal of Experimental Medicine|2006|1.7k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k